[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 1774 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
1st Session
S. 1774
To amend title 5, United States Code, to provide that certain
treatments may not be covered under the health insurance program
carried out under chapter 89 of that title, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 15, 2025
Mr. Risch (for himself, Ms. Lummis, Mr. Ricketts, and Mr. Cramer)
introduced the following bill; which was read twice and referred to the
Committee on Homeland Security and Governmental Affairs
_______________________________________________________________________
A BILL
To amend title 5, United States Code, to provide that certain
treatments may not be covered under the health insurance program
carried out under chapter 89 of that title, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Protecting Minors in Federal Health
Plans Act''.
SEC. 2. PROHIBITIONS ON FEHB COVERAGE FOR CERTAIN TREATMENT.
(a) In General.--Section 8902 of title 5, United States Code, is
amended by adding at the end the following:
``(q)(1) In this subsection, the term `gender-affirming care or
service'--
``(A) means a medical intervention designed to treat gender
dysphoria;
``(B) includes hormone therapy, the use of puberty
blockers, and any surgical procedure aimed at gender
transition; and
``(C) notwithstanding subparagraphs (A) and (B), does not
include--
``(i) a service provided to an individual with a
medically verifiable disorder of sexual development,
including an individual with an irresolvable and
ambiguous external sex characteristic, including an
individual born with--
``(I) 46 XY chromosomes and under-
virilization;
``(II) 46 XX chromosomes and virilization;
or
``(III) both ovarian and testicular tissue;
``(ii) a service provided to treat a disorder
diagnosed by a physician in which the physician has
determined through genetic or biochemical testing that
the applicable individual has abnormal (or otherwise
inconsistent with typical male or female
characteristics)--
``(I) sex chromosome structure;
``(II) sex steroid hormone production; or
``(III) sex steroid hormone action;
``(iii) the treatment of any infection, injury,
disease, or disorder that has been caused or worsened
by a medical intervention described in subparagraph
(A), without regard to whether that intervention--
``(I) was performed in compliance with
State or Federal law; or
``(II) was covered under a contract under
this chapter, as of the date on which the
intervention was performed;
``(iv) any procedure that--
``(I) is performed to address a physical
disorder, injury, or illness that, as certified
by a physician, poses an imminent risk of death
or impairment of major bodily function; and
``(II) is not performed for the purpose of
gender transition or to alleviate
psychological, physical, or mental distress
relating to gender;
``(v) a prescription for puberty suppression or
blocking that is used to normalize puberty in an
individual younger than 18 years of age who has been
diagnosed with precocious puberty;
``(vi) any hormone therapy procedure that is used
to stimulate puberty in an individual younger than 18
years of age who has been diagnosed with delayed
puberty, if the hormones administered through that
procedure are--
``(I) consistent with the biological sex of
the individual; and
``(II) used to stimulate a normal puberty
consistent with the biological sex of the
individual; or
``(vii) male circumcision.
``(2) Subject to paragraph (3), and notwithstanding any other
provision of law or regulation, a contract under this chapter may not
include coverage for any gender-affirming care or service for any
individual younger than 18 years of age.
``(3) In the case of an individual who, as of the effective date of
this subsection, is younger than 18 years of age and who, as of that
effective date, is undergoing hormone therapy that, as of the day
before that effective date, is covered by a contract under this
chapter, that hormone therapy may continue to be covered under such a
contract after that effective date if the hormone therapy is provided
pursuant to a reduction schedule that--
``(A) is supervised by a physician; and
``(B) requires that therapy to conclude not later than 1
year after that effective date.''.
(b) Applicability.--The amendment made by subsection (a) shall
apply with respect to any contract entered into, or renewed for a
contract year, on or after the date of enactment of this Act.
<all>